Phyllodes tumor of the breast: Role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors

Tumor Biology

Volumn 35, Issue 10, 2014, Pages 9603-9612

  Ren, Dongliang ^a   Li, Yanyan ^a   Gong, Yanxin ^a   Xu, Jingchao ^a   Miao, Xiaolong ^a   Li, Xiangnan ^a   Liu, Chen ^a   Jia, Li ^a   Zhao, Yongfu ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Axl; Breast carcinoma; Phyllodes tumor; ST6GalNAcII

Indexed keywords

AXL RECEPTOR TYROSINE KINASE; GALACTOSYL-1-3-N-ACETYLGALACTOSAMINYL-SPECIFIC 2,6-SIALYLTRANSFERASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; SIALYLTRANSFERASE; TRANSCRIPTOME;

ADULT; AGED; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CYSTOSARCOMA PHYLLOIDES; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR INVASION; WESTERN BLOTTING; XENOGRAFT;

ADULT; AGED; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MIDDLE AGED; NEOPLASM INVASIVENESS; PHYLLODES TUMOR; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR PROTEIN-TYROSINE KINASES; SIALYLTRANSFERASES; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84910081357     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2254-9     Document Type: Article

References (48)

1. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ. Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med. 2006; 130: 1516-21.
2. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, et al. Phyllodes tumors of the breast: a clinicopathological analysis of 65 cases from a single institution. Breast. 2009; 18: 165-70.
3. Foxcroft LM, Evans EB, Porter AJ. Difficulties in the preoperative diagnosis of phyllodes tumors of the breast: a study of 84 cases. Breast. 2007; 16: 27-37.
4. Chen WH, Cheng SP, Tzen CY, Yang TL, Jeng KS, Liu CL, et al. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases. J Surg Oncol. 2005; 91: 185-94.
5. Lewitan G, Goldberg C, Cabaleiro C, Espora SM. Phyllodes tumor in a 11 years-old girl: report of a case. Arch Argent Pediatr. 2010; 108(2): 41-3.
6. World Health Organization. Histologic typing of breast tumors, vol. 2. 2nd ed. Geneva, Switzerland: World Health Organization; 1981. p. 22.
7. Ortega E, Aranda FI, Chuliá MT, Niveiro M, Payá A, Seguí J. Phyllodes tumor of the breast with actin inclusions in stromal cells: diagnosis by fine-needle aspiration cytology. Diagn Cytopathol. 2001; 25(2): 115-7.
8. Chen CM, Chen CJ, Chang CL, Shyu JS, Hsieh HF, Harn HJ. CD34, CD117, and actin expression in phyllodes tumor of the breast. J Surg Res. 2000; 94(2): 84-91.
9. Tse GM, Tsang AK, Putti TC, Scolyer RA, Lui PC, Law BK, et al. Stromal CD10 expression inmammary fibroadenomas and phyllodes tumours. J Clin Pathol. 2005; 58(2): 185-9.
10. Tse GM, Ma TK, Chan KF, Law BK, Chen MH, Li KH, et al. Increased microvessel density in malignant and borderline mammary phyllodes tumours. Histopathology. 2001; 38(6): 567-70.
11. Millar EK, Beretov J, Marr P, SarrisM, Clarke RA, Kearsley JH, et al. Malignant phyllodes tumours of the breast display increased stromal p53 protein expression. Histopathology. 1999; 34(6): 491-6.
12. Kuroda N, Sugimoto T, Ueda S, Takahashi T, Moriki T, Sonobe H, et al. Malignant phyllodes tumor of the breast with expression of osteonectin and vinculin. Pathol Int. 2001; 51(4): 277-82.
13. Korshunov VA. Axl-dependent signalling: a clinical update. Clin Sci (Lond). 2012; 122(8): 361-8.
14. Sasaki T, Knyazev PG, Clout NJ, Cheburkin Y, Göhring W, Ullrich A, et al. Structural basis for Gas6-Axl signalling. EMBO J. 2006; 25(1): 80-7.
15. Janssen JW, Schulz AS, Steenvoorden AC, Schmidberger M, Strehl S, Ambros PF, et al. A novel putative tyrosine kinase receptor with oncogenic potential. Oncogene. 1991; 6: 2113-20.
16. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991; 11: 5016-31.
17. Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, et al. Multipleroles for the receptor tyrosine kinase axl in tumor formation. Cancer Res. 2005; 65(20): 9294-303.
18. Linger R, KeatingAK, EarpHS, GrahamDK. TAMreceptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008; 100: 35-83.
19. Dall'Olio F, Chiricolo M. Sialyltransferases in cancer. Glycoconj J. 2001; 18: 841-50.
20. Dwek RA. Glycobiology: toward understanding the function of sugars. Chem Rev. 1996; 96: 683-720.
21. Ihara S, Miyoshi E, Ko JH, Murata K, Nakahara S, Honke K, et al. Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching. J Biol Chem. 2002; 277: 16960-7.
22. Li J, Jia L, Ma ZH, Ma QH, Yang XH, Zhao YF. Axl glycosylation mediates tumor cell proliferation, invasion and lymphatic metastasis in murine hepatocellular carcinoma. World J Gastroenterol. 2012; 18(38): 5369-76.
23. Harvey BE, Toth CA, Wagner HE, Steele Jr GD, Thomas P. Sialyltransferase activity and hepatic tumor growth in a nude mouse model of colorectal cancer metastases. Cancer Res. 1992; 52: 1775-9.
24. Majuri ML, Niemela R, Tiisala S, Renkonen O, Renkonen R. Expression function of alpha 2, 3-sialyl-and alpha 1, 3/1, 4-fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin counter-receptors. Int J Cancer. 1995; 63: 551-9.
25. Yogeeswaran G, Salk PL. Metastatic potential is positively correlated with cell surface sialylation of cultured murine tumor cell lines. Science. 1981; 212: 1514-6.
26. Dennis J, Waller C, Timpl R, Schirrmacher V. Surface sialic acid reduces attachment of metastatic tumour cells to collagen type IVand fibronectin. Nature. 1982; 300: 274-6.
27. Marcos NT, Pinho S, Grandela C, Cruz A, Samyn-Petit B, Harduin-Lepers A, et al. Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res. 2004; 64: 7050-7.
28. Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, Karsten U, et al. Overexpression of sialyltransferase CMP-sialic acid: Galbeta 1, 3GalNAc-R alpha6-sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res. 2001; 11: 4605-11.
29. Xu LX, Zhao MH. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy. Kidney Int. 2005; 68: 167-72.
30. Ding JX, Xu LX, Lv JC, Zhao MH, Zhang H, Wang HY. Aberrant sialylation of serum IgA1 was associated with prognosis of patients with IgA nephropathy. Clin Immunol. 2007; 125: 268-74.
31. Ding JX, Xu LX, Zhu L, Lv JC, ZhaoMH, Zhang H. Activity of a2, 6-sialyltransferase and its gene expression in peripheral B lymphocytes in patients with IgA nephropathy. Scand J Immunol. 2009; 69: 174-80.
32. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van der Vijver MJ. WHO classification of tumours of the breast. Geneva: WHO; 2012.
33. Xu J, Jia L, Ma H, Li Y, Ma Z, Zhao Y. Axl geneknockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway. Tumour Biol. 2013.
34. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002; 8: 361-7.
35. Vajkoczy P, Knyazev P, Kunkel A, Capelle HH, Behrndt S, von Tengg-Kobligk H, et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A. 2006; 103: 5799-804.
36. Tai KY, Shieh YS, Lee CS, Shiah SG, Wu CW. Axl promotes cell invasion by inducing MMP-9 activity through activation of NFkappaB and Brg-1. Oncogene. 2008; 27: 4044-55.
37. Christofori G. New signals from the invasive front. Nature. 2006; 41: 444-50.
38. Zhang YX, Knyazev PG, Cheburkin YV, Sharma K, Knyazev YP, Orfi L, et al. AXL is potential target for therapeutic intervention in breast cancer progression. Cancer Res. 2008; 68: 1905-15.
39. Apweiler R, Hermjakob H, Sharon N. On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. Biochim Biophys Acta. 1999; 1473: 4-8.
40. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 1996; 56: 5309-18.
41. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006; 126: 855-67.
42. Zhao YF, Li YP, Ma HY, Dong WJ, Zhou HM, Song XB, et al. Modification of sialylation mediates the invasive properties and chemosensitivity of human hepatocellular carcinoma. Mol Cell Proteomics. 2014; 13(2): 520-36.
43. Ding DX, Vera JC, Heaney ML, Golde DW. N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit is essential for ligand binding and signal transduction. J Biol Chem. 1995; 270: 24580-4.
44. Li Y, Ye X, Tan C, Hongo JA, Zha J, Liu J, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009; 28(39): 3442-55.
45. Gjerdrum C, Tiron C, Høiby T, Stefansson I, Haugen H, Sandal T, et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010; 107(3): 1124-9.
46. Saxon E, Bertozzi CR. Chemical and biological strategies for engineering cell surface glycosylation. Annu Rev CellDev Biol. 2001; 17: 1-23.
47. Taniguchi N, Miyoshi E, Gu J, Honke K, Matsumoto A. Decoding sugar functions by identifying target glycoproteins. Curr Opin Struct Biol. 2006; 16: 561-6.
48. Ren DL, Jia L, Li YY, Gong YX, Liu C, Zhang X, et al. ST6GalNAcII mediates the invasive properties of breast carcinoma through PI3K/Akt/NF-kB signaling pathway. IUBMB Life. 2014; 66(4): 300-8.